MX2015000980A - Inhibidores de aril lactama cinasa. - Google Patents

Inhibidores de aril lactama cinasa.

Info

Publication number
MX2015000980A
MX2015000980A MX2015000980A MX2015000980A MX2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A MX 2015000980 A MX2015000980 A MX 2015000980A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
aryl lactam
lactam kinase
aryl
compounds
Prior art date
Application number
MX2015000980A
Other languages
English (en)
Spanish (es)
Inventor
Vivekananda M Vrudhula
Senliang Pan
Ramkumar Rajamani
John E Macor
Joanne J Bronson
Carolyn Diane Dzierba
Susheel Jethanand Nara
Maheswaran Sivasamban Karatholuvhu
Tarun Kumar Maishal
Jonathan L Ditta
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2015000980A publication Critical patent/MX2015000980A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2015000980A 2012-07-31 2013-07-24 Inhibidores de aril lactama cinasa. MX2015000980A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors
PCT/US2013/051831 WO2014022167A1 (en) 2012-07-31 2013-07-24 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015000980A true MX2015000980A (es) 2015-04-10

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000980A MX2015000980A (es) 2012-07-31 2013-07-24 Inhibidores de aril lactama cinasa.

Country Status (12)

Country Link
US (1) US8901305B2 (enExample)
EP (1) EP2880032B1 (enExample)
JP (1) JP2015528018A (enExample)
CN (1) CN104507941A (enExample)
AR (1) AR093758A1 (enExample)
BR (1) BR112015001890A2 (enExample)
CA (1) CA2880523A1 (enExample)
EA (1) EA201590268A1 (enExample)
ES (1) ES2602965T3 (enExample)
MX (1) MX2015000980A (enExample)
TW (1) TW201410676A (enExample)
WO (1) WO2014022167A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN106132414A (zh) * 2014-01-29 2016-11-16 百时美施贵宝公司 芳基内酰胺激酶抑制剂
CA2944466C (en) 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
EP3356330B1 (en) * 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
CN108368084B (zh) * 2015-10-01 2020-10-16 百时美施贵宝公司 联芳基激酶抑制剂
WO2021026349A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
BR9307570A (pt) 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CA2477692A1 (en) 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2555287A1 (en) * 2004-02-18 2005-08-25 David Garrett Loughhead Heterocyclic gaba-a subtype selective receptor modulators
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
KR20080063833A (ko) * 2005-12-15 2008-07-07 에프. 호프만-라 로슈 아게 트리시클릭 락탐 유도체, 이의 제조 및 약학적 제제로서의용도
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
CA2645031A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2008022155A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
JP5752232B2 (ja) * 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
DK2822555T3 (en) 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
NZ630719A (en) 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
IN2014DN07384A (enExample) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc

Also Published As

Publication number Publication date
ES2602965T3 (es) 2017-02-23
JP2015528018A (ja) 2015-09-24
EP2880032B1 (en) 2016-10-05
US20140038999A1 (en) 2014-02-06
CA2880523A1 (en) 2014-02-06
TW201410676A (zh) 2014-03-16
EP2880032A1 (en) 2015-06-10
WO2014022167A1 (en) 2014-02-06
CN104507941A (zh) 2015-04-08
EA201590268A1 (ru) 2015-05-29
BR112015001890A2 (pt) 2017-07-04
AR093758A1 (es) 2015-06-24
US8901305B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
MX2016012829A (es) Inhibidores de biaril cinasa.
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
PH12017502141A1 (en) Compounds and their methods of use
MX2012013197A (es) Inhibidores de indazol de cinasa.
HK1220355A1 (zh) Mk2抑制劑和其用途
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2016009355A (es) Inhibidores de aril lactama cinasa.
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX342879B (es) Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
PH12016501071B1 (en) Serine/threonine kinase inhibitors
AU2015292632B2 (en) Aldosterone synthase inhibitors
IN2014CN04050A (enExample)
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
MA39824A (fr) Composés azole amido-substitués
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors